Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasms 2Head and Neck Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Laryngeal Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Carboplatin 369Pemetrexed 310pembrolizumab 303Cisplatin 244Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28tislelizumab 26cemiplimab 26avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × monalizumab × Clear all
NCT05061550 2026-05-22

NeoCOAST-2

AstraZeneca

Phase 2 Recruiting
630 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05221840 2026-05-18

PACIFIC-9

AstraZeneca

Phase 3 Active not recruiting
1,051 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03822351 2024-10-08

COAST

MedImmune LLC

Phase 2 Completed
189 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03794544 2022-02-24

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

MedImmune LLC

Phase 2 Completed
84 enrolled 17 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡